Tesaro's Rolapitant Fails Secondary Goals

Tesaro Inc. (Nasdaq: TSRO) reported that its chemotherapy induced nausea and vomiting treatment rolapitant failed to meet secondary endpoints in two Phase 3 studies. Shares of the biopharmaceutical plummeted $9.33 to close at $28.37.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here